XBiotech shares tank af­ter PhI­II da­ta get a roast­ing

The last time we checked in with Austin-based XBiotech $XBIT, the com­pa­ny was try­ing to ex­plain how it had screwed up a Phase III study of its lead drug Xilonix, con­fus­ing da­ta on about 25% of its pa­tients.

Over the week­end the com­pa­ny put out a batch of that da­ta, and in­clud­ed this in­ter­est­ing note:

“Among re­spon­ders (in both treat­ment and place­bo arms), clin­i­cal re­sponse was as­so­ci­at­ed with a 2.7-fold in­crease in over­all sur­vival (11.5 ver­sus 4.2 months in re­spon­ders vs. non-re­spon­ders, re­spec­tive­ly). Over­all sur­vival was not com­pared be­tween treat­ment arms be­cause af­ter 8 weeks, all pa­tients were el­i­gi­ble to re­ceive study drug.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER